



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

CINEPAZIDE MALEATE INJECTION (KELINAO®) OF SIHUAN PHARMACEUTICAL OBTAINED APPROVAL FOR NEW INDICATION

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group’s Cinepazide Maleate Injection (Kelinao® 2ml: 80mg per unit and Anjieli® 10ml: 320mg per unit) for the treatment of new indication of acute ischemic stroke has successfully obtained the approval from the National Medical Products Administration (“**NMPA**”) of the People’s Republic of China (“**China**”) at the end of 2020. The Cinepazide Maleate Injection (Kelinao®) of the Group is currently the only approved drug in the field of stroke treatment since the commencement of the domestic post-marketing clinical study for drugs.

Cinepazide Maleate Injection (Kelinao®) is a kind of weak calcium ion antagonist with a unique synergism of endogenous adenosine, and it can effectively improve the blood supply in the cerebral ischemic area. As the first marketed Cinepazide Maleate Injection in China, Kelinao® has been widely used in the treatment of cardiovascular, cerebrovascular and peripheral vascular diseases since 2002, and accumulated clinical use experience of more than 6 million people, which demonstrated a good safety profile.

The stroke is a “Four High” disease with high incidence, high disability, high mortality and high recurrence rate. The China Burden of Disease Report published on the “Lancet” in 2019 showed that the stroke has been the most common death cause for the Chinese population from 1990 to 2017, and there were more than 2 million new patients of stroke every year, which ranked the first in the world.

According to data from IQVIA, the market size of stroke prescription drugs in China has reached RMB120 billion in 2019. The Group's Cinepazide Maleate Injection (Kelinao[®]) for the treatment of new indication of acute ischemic stroke was approved by NMPA, which proved its clinical value as the treating medicine for the cerebrovascular disease. It will bring treatment benefits for more unmet stroke patients in the future, and have positive impact on the operation results of the Group.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By Order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 27 January 2021

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Kim Jin Ha; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.